Skip to main content
Premium Trial:

Request an Annual Quote

NCI Proteomics Office Inks MOUs with FDA, NHLBI

NEW YORK (GenomeWeb News) – The National Cancer Institute said today that it has struck two new partnerships, one with the National Heart, Lung, and Blood Institute and another with the Food and Drug Administration, to develop and support new proteomics research projects through its Office of Cancer Clinical Proteomics Research, or OCCPR.

Under one memorandum of understanding, OCCPR and NHLBI's Proteomics Center Program agreed to extend a collaboration under which the partners will share reagents and protocols and develop bioinformatics standards for studies that use proteomics tools to understand cancer and cardiovascular and lung diseases.

The NCI proteomics office also signed an MOU with the FDA to formally extend a collaboration with FDA's Office of In Vitro Diagnostic Device Evaluation and Safety.

Under this agreement, the partners will work on statistical experimental design, analytical validation of instruments, informatics, and biospecimen sample preparations, as they are related to clinical cancer diagnostics and cancer therapeutics.

OCCPR's core efforts include integrating proteomics technologies with publicly accessible data, reagents, reference materials, and analysis systems, with the larger aim of supporting cancer research. The office also manages the Clinical Proteomic Tumor Analysis Consortium and represents a network of Protein Characterization Centers that coordinate proteomics studies of genomically characterized cancer specimens.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.